Previous 10 | Next 10 |
2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...
2024-04-07 06:30:00 ET Summary ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Franciscoȁ...
2024-04-06 15:21:29 ET More on Bristol-Myers Squibb Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis) Bristol Myers Squibb: The Comeback Is Unfolding Bristol-Myers Squibb Is Not A Buy For Me Bristol Myers, 2seventy bio's Abecma ap...
KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of treatment A majority of patients (65%) experienced reductions in weight over the course of the trial, with a mean weight decrea...
Long-term treatment with KarXT was associated with continued improvements in symptoms of schizophrenia across all efficacy measures at 52 weeks More than 75% of participants achieved > 30% improvement in symptoms from baseline, as measured by the Positive and Negative Syndrome ...
2024-04-06 09:30:00 ET Summary This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks ...
2024-04-06 08:38:09 ET More on Johnson & Johnson Johnson & Johnson: Self-Proclaimed 'Dividend King' Faces Tricky Outlook With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back Johnson & Johnson (JNJ) Barclays 26th Annual Global Healthcare ...
2024-04-05 09:33:47 ET Bristol Myers Squibb ( NYSE: BMY ) said on Friday that the company and 2seventy bio ( NASDAQ: TSVT ) received U.S. FDA approval for Abecma in the treatment of adult patients with relapsed or refractory multiple myeloma.... Rea...
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile Expanded approval brings this personalized CAR T cell therapy to more pati...
2024-04-04 11:12:55 ET More on Health Care Select Sector SPDR: XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...